



HHS Public Access

Author manuscript

Pathog Immun. Author manuscript; available in PMC 2019 January 15.

Published in final edited form as:

Pathog Immun. 2018 ; 3(2): 197–223. doi:10.20411/pai.v3i2.263.

Incomplete Suppression of HIV-1 by SAMHD1 Permits Efficient Macrophage Infection

Timothy Plitnik¹, Mark E. Sharkey², Bijan Mahboubi^{3,4}, Baek Kim^{3,4,5}, and Mario Stevenson^{1,2}

¹Department of Microbiology & Immunology; Miller School of Medicine, University of Miami; Miami, Florida

²Department of Medicine; Miller School of Medicine, University of Miami; Miami, Florida

³Department of Pediatrics, Emory University; Atlanta, Georgia

⁴Center for Drug Discovery, Children's Healthcare of Atlanta; Atlanta, Georgia

⁵Department of Pharmacy, Kyung-Hee University; Seoul; South Korea.

Abstract

Background: Sterile alpha motif and histidine/aspartic acid domain-containing protein (SAMHD1) is a dNTP triphosphorylase that reduces cellular dNTP levels in non-dividing cells, such as macrophages. Since dNTPs are required for reverse transcription, HIV-2 and most SIVs encode a Vpx protein that promotes proteasomal degradation of SAMHD1. It is unclear how HIV-1, which does not appear to harbor a SAMHD1 escape mechanism, is able to infect macrophages in the face of SAMHD1 restriction.

Methods: To assess whether HIV-1 had a mechanism to negate SAMHD1 activity, we compared SAMHD1 and dNTP levels in macrophages infected by HIV-1 and SIV. We examined whether macrophages infected by HIV-1 still harbored antiviral levels of SAMHD1 by assessing their susceptibility to superinfection by *vpx*-deleted SIV. Finally, to assess whether HIV-1 reverse transcriptase (RT) has adapted to a low dNTP environment, we evaluated SAMHD1 sensitivity of chimeric HIV-1 and SIV variants in which the RT regions were functionally exchanged.

Results: Here, we demonstrate that HIV-1 efficiently infects macrophages without modulating SAMHD1 activity or cellular dNTP levels, and that macrophages permissive to HIV-1 infection remained refractory to superinfection by *vpx*-deleted SIV. Furthermore, through the use of chimeric HIV/SIV, we demonstrate that the differential sensitivity of HIV-1 and SIV to SAMHD1 restriction is not dictated by RT.

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

CORRESPONDING AUTHOR Mario Stevenson MStevenson@med.miami.edu.

AUTHOR CONTRIBUTIONS

Conceptualization, T.P. and M.S.; Methodology, T.P., M.E.S.; Investigation, T.P. and B.M.; Resources, T.P., B.M., B.K., M.S., M.E.S.; Writing – Original Draft, T.P. and M.S.; Writing – Review & Editing, T.P. and M.S.; Funding Acquisition, M.S. and B.K.; Supervision, M.S.

CONFLICT OF INTEREST

The authors have no competing financial interests.

Conclusions: Our study reveals fundamental differences between HIV-1 and SIV in the strategy used to evade restriction by SAMHD1 and suggests a degree of resistance of HIV-1 to the antiviral environment created by SAMHD1. Understanding how these cellular restrictions antagonize viral replication will be important for the design of novel antiviral strategies.

Keywords

HIV-1; macrophages; SAMHD1

INTRODUCTION

The replication of primate lentiviruses is antagonized by several cellular factors, collectively referred to as antiviral restrictions. These include APOBEC3G, Tetherin/BST2, and Sterile alpha motif and histidine/aspartic acid domain-containing protein (SAMHD1). Primate lentiviruses have evolved strategies to counteract these restrictions thus allowing infection of, and replication within, host cells. APOBEC3G is countered by the accessory protein Vif, Tetherin/BST2 is neutralized by Vpu, and SAMHD1 is nullified by Vpx which is expressed by HIV-2 and most SIVs. In each case, the viral defense protein targets the cellular restriction for proteasomal destruction [1].

SAMHD1 limits dNTP concentrations in non-dividing cells where high levels of dNTPs would be excessive to need [2]. Non-cycling cells need to maintain low levels of dNTPs to prevent the buildup of cytosolic nucleic acid that could trigger innate immune responses [2, 3]. SAMHD1 is preferentially expressed in macrophages which are an important target cell for primate lentivirus infection as well as dendritic cells and quiescent CD4⁺ T cells [4]. SAMHD1 is a GTP-activated nucleotide triphosphohydrolase, which converts dNTPs into deoxyribonucleosides and triphosphates [2, 5–7]. SAMHD1 is responsible for the inhibition of a wide range of viruses and retroviruses in myeloid cells [8–10], and defects in SAMHD1 can cause Aicardi-Goutières Syndrome, an autoimmune disorder characterized by persistent immune activation [11, 12]. Most reports agree that SAMHD1 restricts infection through its dNTPase activity, though there are some reports indicating that RNase activity is required for antiviral restriction [13]. The antiviral activity of SAMHD1 is further regulated via its phosphorylation status, being more active in non-cycling cells or after interferon and cytokine exposure [11, 14, 15].

The antiviral action of SAMHD1 is opposed by the lentiviral accessory protein Vpx, which is encoded by HIV-2 and most SIVs but is absent from HIV-1. In the presence of SAMHD1, cellular dNTP concentrations are suboptimal for reverse transcription of viral cDNA [2, 16, 17]. Indeed, for SIV variants lacking a functional *vpx* allele, macrophages are completely refractory to infection [9, 18, 19]. This therefore requires that primate lentiviruses eliminate SAMHD1 for reverse transcription to occur. As such, Vpx is encapsidated in the virion through interaction with Gag p6 [20, 21]. This allows rapid delivery of Vpx upon cytosolic discharge of the viral core. Following fusion of viral and cellular membranes, SAMHD1 is rapidly recruited by Vpx to the DCAF1/Cullin/E3 Ubiquitin Ligase complex and subsequently tagged for proteasomal degradation [2, 7, 22–24]. SAMHD1 can also be eliminated *in trans* through the addition of Vpx-containing virus-like particles (Vpx-VLPs)

thereby augmenting macrophage infection by SIV/HIV-2, HIV-1, and other retroviruses [2, 9, 22]. Upon SAMHD1 degradation, intracellular dNTP levels rapidly increase to levels conducive to efficient reverse transcription [7, 22, 25, 26]. Therefore, maintaining low cellular dNTP levels represents a potent mechanism for preventing reverse transcription and viral infection [2, 8, 27, 28].

HIV-1 presents a conundrum with regards to SAMHD1 evasion. HIV-1 encodes a structurally similar Vpx paralog termed Vpr, which likely evolved through duplication of an ancestral *vpx* allele [29–31]. Vpx proteins from different SIV strains exhibit differential binding to SAMHD1, and some SIVs encode Vpr proteins that can bind SAMHD1 [29, 30, 32]. It has been hypothesized that HIV-1 Vpr may have some SAMHD1 degradation properties as it also binds DCAF1 [33, 34]. However, despite similarities between the proteins, HIV-1 Vpr appears unable to substitute for SIV Vpx in enhancing macrophage infection in the presence of SAMHD1 [19].

A number of studies have turned to HIV-1 reverse transcriptase (RT) to possibly explain how HIV-1 can infect macrophages in the face of SAMHD1 restriction. Studies show that the lentiviral RTs are exceptionally good at operating at low dNTP levels, much more so than other retroviruses [35–37]. Several studies have reported that the K_m of HIV-1 RT for dNTPs is above the levels found in macrophages [17, 38]. This has prompted investigators to suggest that HIV-1 RT has evolved to operate in a low dNTP environment thus enabling macrophage infection without the need to evade SAMHD1 [39, 40]. Here we investigate the impact of SAMHD1 on permissivity of macrophages to HIV-1 infection. Specifically, we assessed whether HIV-1 promotes SAMHD1 degradation or modulates its antiviral activity, whether HIV-1 modulates dNTP levels, and finally, whether RT influences the ability of HIV-1 to evade SAMHD1 restriction.

METHODS

Cell Culture

Elutriated human monocytes from anonymous donors were shipped overnight from the University of Nebraska Medical Center. The cells were further processed with EasySep™ Human Monocyte Isolation Kit (StemCell Technologies) and differentiated for 7 days under standard tissue-culture conditions (37°C, 5% CO₂) in the presence of recombinant human M-CSF (R&D Systems) at 10 ng/mL in macrophage growth media comprised of 1xDMEM containing 10% heat-inactivated human serum (SeraCare Life Sciences), 1% 200mM L-Glutamine (Gibco), and 0.1% Gentamicin (Sigma). Isolated monocytes were plated in 24-well polypropylene plates at a density of ~0.5–0.75e6 cells/well in 1.5 mL [41]. HEK293T cells were cultured in 1xDMEM containing 10% heat-inactivated FBS (Hyclone), 1% 200mM L-Glutamine (Gibco), and 1% Pen-Strep (Gibco). In addition, sMAGI cells were obtained from the AIDS Reagent Program and cultured as described [42].

Viral Molecular Clone Generation

The molecular clone, SIVsmm PBj1.9 (SIVwt) and its counterpart lacking a functional *vpx* allele (SIV vpx) are as previously described [18]. HIV-1 LAIada is a macrophage tropic

HIV-1 variant in which the infectious HIV-1 molecular clone LAI contains a portion of the envelope of macrophage tropic HIV-1 ADA [43]. SIV ν px+Vpx, in which Vpx is packaged *in trans*, was generated by co-transfection of the SIVsmm PBjX2 (SIV ν px) plasmid with a CMV-driven SIV PBj Vpx expression plasmid. SIVwt-GFP and SIV ν px-GFP are clones of PBj that contain a GFP gene inserted in place of Env [19]. HIV-1-GFP contains a GFP gene inserted in Nef [19]. The chimeric virus RT-SHIV (in which HIV-1 RT from LAI is inserted in an SIV PBj backbone in place of SIV RT) was generated using Exponential Megapriming PCR [44] and Q5 High-Fidelity DNA Polymerase (New England Biolabs). Primers used were as follows: SHIV-F1-CCCATTAGTCCTATTGAAACTGTACCAGTA; SHIV-R1-GCGCTGGTTCTATTTTTTCTAAGAATAGTACTTTTCTGATTCCAGACGT; SHIV-R2-GAGATTTAGAGACATACCCATAGCTGTTAG. The following primers were used to generate RT-HSIV, (in which the RT from SIV PBj is inserted into an HIV-1 LAI backbone): HSIV-F1-CCCATAGCTAAGGTAGAGCCTATAAAAGTA; HSIV-R1-GGGCCTTATCTATTCCATCTAAAATAGGACTTGTCTAATTCCTTGACTA; HSIV-R2-AAAATTTAAAGTGCAACCAATCTGAGTCAA. Full-length SIVmac316e WT and ν px were generated by combining plasmids containing the 5' end of SIVmac239 (wild type and ν px) with the 3' end of SIVmac316e. RT-SHIVmac316e wild type and ν px were generated by recombining the RT containing region of a RT-SHIVmac239 plasmid with the respective full-length SIVmac316e plasmids. All SIV/RT-SHIVmac plasmids were kindly provided by the laboratory of Ronald C. Desrosiers, PhD at the University of Miami [45–47].

Generation of Viral Stocks

Infectious virus stocks were generated by Lipofectamine[®] 2000 (Thermo Fisher) transfection of HEK293T cells. Vesicular Stomatitis Virus glycoprotein (VSVg)-transcomplementation was used with HIV-1, SIV, RT-SHIV, and RT-HSIV clones to increase the infectivity of the viral stocks [48, 49]. A plasmid expressing SIVsmm PBj Vpx was also co-transfected to generate SIVs with Vpx added *in trans*. Transfected cell supernatants were harvested 48 and 72 hours post-transfection, concentrated over a 20% sucrose gradient by ultra-centrifugation, and stored at -80°C until use. Viral stocks were quantified by commercially available p24 or p27 ELISAs for HIV-1 and SIV preparations respectively (Advanced Bioscience Laboratories).

Macrophage Infection

Macrophages in 24-well plates were infected (50 ng of p24 or p27 per well) for 4–6 hours at 37°C , after which cells were washed with PBS, and virus-containing media was replaced with fresh media. In some cases, spinoculation (centrifugation at $1200g$ for 2 hours at 25°C) was also used to increase viral infectivity. At specified time points post-infection, total DNA was extracted using ZR-96 Quick-gDNA[™] kits (Zymo Research). To gauge the contribution of carryover plasmid DNA to the cDNA measurements, antiretroviral drugs were added at supra-inhibitory concentrations ($400\mu\text{M}$ Tenofovir or $2\mu\text{M}$ Nevirapine) at least 2 hours before infection and maintained throughout the infection.

SAMHD1 Knock-Down

Macrophages were transfected with 60 pmol SAMHD1-specific siRNA using GenMute™ siRNA Transfection Reagent for Primary Macrophages (SignaGen Laboratories) according to the manufacturer's instructions. Cells were again transfected on day 4 and day 8 after the initial transfection (total of 3 transfections). Cells were ready for infection or lysis 14 days after the initial transfection. The following siRNAs were used: SAMHD1 silencer select siRNA (Thermo Fisher Scientific); Silencer® Select Negative Control No. 1 siRNA (Life Technologies). Lyophilized siRNAs were re-hydrated in 1x siRNA Buffer (Dharmacon) at a concentration of 20nM and stored at -20°C.

Western Blots

Cells were lysed using RIPA Lysis and Extraction Buffer (Life Technologies) with Halt™ Protease and Phosphatase Inhibitor Cocktail (Life Technologies). Total protein was quantified by EZQ™ Protein Quantitation Kit (Thermo Fisher Scientific). Lysates were denatured using NuPAGE® LDS sample buffer and reducing reagent (Life Technologies). Samples were run on NuPAGE® Bis-Tris Gels (Life Technologies) and transferred to a nitrocellulose membrane using iBlot® Transfer Stack (Life Technologies). Antibodies used were as follows: Anti-SAMHD1 antibody, clone 3F5 (Abcam); GAPDH antibody, clone 2D9 (Origene). MagicMark™ XP Western Protein Standard (Life Technologies) was used as a molecular weight standard. Densitometry analysis was performed using ImageJ 1.50i software.

Quantification of Reverse Transcripts

Levels of 2LTR circles, a marker of complete reverse transcription, were determined using TaqMan® Fast Universal PCR Master Mix (Life Technologies) on an Applied Biosystems® 7500 Fast Real-Time PCR System. In each 20 µL reaction (performed in duplicate) 5 µL of total DNA was used. The 2LTR circles were normalized to CCR5 copy number (cell equivalents). Samples were quantified using standard curves of known quantities of each amplicon. Primer/Probes sets were as follows: CCR5: CCR5F- GCTGTCTTTGCGTCTCTCCCAGGA; CCR5R- CTCACAGCCCTGTGCCTCTTCTTC; CCR5probe- /56FAM/AGCAGCGGC/ZEN/AGGACCAGCCCCAAG/3IABkFQ/; SIV: PBjn/f- AGAAGCCCCTGGTCTGTTAGGAC; PBjc/r- TCGTCTTCCTGAGCTTCATCTGA; PBjprobe- /56-FAM/TGGCAAAT/ZEN/ TACACAGCAGGGCCAG/3IABkFQ/; HIV-1: HIV1F- TAGACCAGATCTGAGCCTGGGA; HIV1R- GTAGTTCTGCCAATCAGGGAAG; HIV1probe- /56FAM/AGCCTCAAT/ZEN/ AAAGCTTGCCCTTGAGTGC/3IABkFQ/.

Flow Cytometry

Macrophages were stained with LIVE/DEAD® Fixable Near-IR Dead Cell Stain Kit (Thermo Fisher) and fixed in 4% paraformaldehyde. They were then detached with Accutase™ Cell Detachment Solution (StemCell Technologies™), permeabilized with an NP-40 solution, blocked with Human TruStain FcX™ solution (Biolegend), and stained with anti-HIV-1 Core Antigen, Clone: KC57-RD1 (Beckman Coulter™) and Alexa-488 Anti-

SAMHD1 (I-1918) antibody, kindly provided by the Olivier Schwartz at the Pasteur Institute [26]. Data was analyzed on FlowJo v10.1 software.

dNTP Assay

For dNTP extraction, cells were lysed in 65% ice-cold methanol. Lysates were then vortexed for 2 minutes, heated to 95°C for 3 minutes, cooled on ice for 2 minutes, and subsequently centrifuged to clear debris. Cleared lysates were then dried using a speed-vac at 50°C. The dried lysates were frozen at -80°C until analysis. The dNTP concentrations were determined by the Baek Kim Laboratory at Emory University as previously described [17].

RT-Assay

After infection, aliquots of supernatant were harvested at several time-points and frozen at -20°C until ready to be assayed using a previously established protocol [50]. Briefly, frozen supernatant was thawed, and 5 µL was incubated for 15 minutes at 37°C in a 96-well round-bottom plate with 10 µL of Solution A (100mM Tris-HCl, 300mM KCl, 10mM DTT, 0.1% NP40) to lyse the virus. Next, 25 µL of Solution B (50mM Tris-HCl, 150mM KCl, 5mM DTT, 0.5% NP40, 15mM MgCl₂, 0.5 U/mL PolyA-Oligo dT, and 30 µCi ³H-dTTP) was added to each well, and the plate was incubated at 37°C overnight. The next day, 5 µL of the reaction was spotted onto Whatman DEAE filter paper, washed 3 times with 5% Na₂HPO₄, washed with DI water, washed with 70% Ethanol, dried, and read in a scintillation counter for 60 seconds.

Statistics

Data was analyzed on Prism 7 software. Data comparisons between 2 experimental groups were analyzed by an unpaired *t* test with Welch's correction or by area under the curve analysis. *P* values are denoted as **P*<0.05, ***P*<0.01, ****P*<0.001, and *****P*<0.0001. All graphs, unless otherwise stated, represent pooled data from at least 3 or more separate, replicate experiments +/- SD.

RESULTS

SAMHD1 is Modulated by SIV, But Not HIV-1 Infection.

The lack of a Vpx-like function in HIV-1 would prompt speculation that macrophages are refractory to HIV-1 infection. Therefore, we first assessed whether HIV-1 can infect macrophages as robustly as SIV. Monocyte-derived macrophages were infected with wild-type HIV-1 or SIV (HIV-1 or SIVwt) that were transcomplemented with VSVg. Spinoculation was further employed to promote efficient and synchronous infection of macrophages [28, 48]. Three to 4 days after infection, cells were analyzed for co-expression of HIV-1 or SIV Gag and SAMHD1 by flow cytometry (Figure 1A, B). Individual profiles and collated profiles are shown in A and B respectively. As expected, SIV Gag-positive macrophages expressed very low levels of SAMHD1, while in contrast, HIV-1 Gag-positive cells expressed levels of SAMHD1 similar to those in uninfected cells (Figure 1A, B). Statistical comparison of Gag and SAMHD1 levels in SIV- and HIV-1-infected cells (Figure 1C, D) confirmed that not only do both HIV-1 and SIV infect macrophages at comparable levels (30% +/- 4.4% for HIV-1 and 48% +/- 6.1% for SIV), but only SIV infection of

macrophages led to elimination of SAMHD1. HIV-1 infection, however, did not alter SAMHD1 levels in macrophages as drastically, and the levels were more comparable to those seen in uninfected cells (Figure 1D). The slightly higher SAMHD1 levels observed in HIV-1-infected macrophages are likely due to spectral overlap between the fluorochromes (PE and Alexa488).

To confirm the flow cytometry results, we next examined SAMHD1 levels in infected cells by Western blotting. Western blots of infected macrophage lysates revealed a similar pattern of SAMHD1 degradation in SIVwt-infected but not HIV-1-infected or *vpx*-deleted SIV (SIV *vpx*)-infected macrophages (Figure 1E, F). In SIVwt-infected macrophages, SAMHD1 was not detectable (Figure 1E, F). In contrast, SAMHD1 levels in HIV-1-infected cells were comparable to those in uninfected cells despite similar levels of Gag+ cells from wells sampled for flow cytometry (37% +/- 7.4% for HIV-1 and 43% +/- 6.1% for SIVwt) (Figure 1F, G). Not surprisingly, SIV *vpx* did not affect SAMHD1 levels and was restricted from infection (Figure 1E, F, G). Densitometry demonstrated no significant differences in SAMHD1 levels between HIV-1-infected, SIV *vpx*-infected, and uninfected macrophages (Figure 1F).

Hypothetically, it was possible that HIV-1 used a mechanism, independent of SAMHD1 degradation, to augment dNTP levels and create conditions conducive to reverse transcription. Therefore, we measured intracellular dNTP levels in HIV-1- and SIV-infected macrophages. As expected, infection of macrophages with SIV led to an increase in dNTP levels, in particular dATP and dGTP, compared with levels in uninfected cells (Figure 1H). In contrast, dNTP levels in HIV-1-infected and SIV *vpx*-infected macrophages were similar to those in uninfected macrophages (Figure 1H). Collectively, these results indicate that HIV-1 undergoes macrophage infection without modulating cellular SAMHD1 or dNTP levels. The results also confirm previous findings that SIV is dependent on SAMHD1 depletion and dNTP modulation [7, 8, 19, 23, 51]. This suggests that HIV-1 may exhibit some degree of intrinsic resistance to the antiviral environment created by SAMHD1.

SAMHD1 Knock-Down Impacts Macrophage Permissivity to Lentiviral Infection

To further confirm the antiviral effects of SAMHD1, we examined the effect of SAMHD1 depletion on macrophage infectivity. SAMHD1 has a long half-life, so we developed a triple siRNA transfection strategy to fully deplete SAMHD1 levels in primary macrophages [22, 52]. Unlike other studies that rely on monocytic cell-lines or partial knockdown, our strategy was effective in depleting SAMHD1 in primary human monocyte-derived macrophages to levels undetectable by Western blotting (Figure 2A) [2, 22, 23, 53–57]. Densitometry analysis confirmed that the SAMHD1-targeting siRNA led to depletion of SAMHD1 to levels below both those of scrambled siRNA ($P<0.01$) and mock transfection ($P<0.001$) (Figure 2B). SAMHD1-depleted macrophages were then infected with SIVwt or SIV *vpx*, and infection was monitored by the level of viral cDNA (2LTR circles) by qPCR. Although 2LTRs are unintegrated episomal products of reverse transcription, they nonetheless serve as convenient indicators of viral infection under single-round conditions [58]. To demonstrate that cDNA products detected in infected macrophages were synthesized *de novo*, macrophages were infected in the presence and absence of supra-inhibitory concentrations

of the RT inhibitor tenofovir. While the scrambled siRNA and mock transfection conditions had little to no detectable viral cDNA for SIV vpx, depletion of SAMHD1 mediated by SAMHD1-siRNA increased viral cDNA levels in SIV vpx-infected macrophages comparable to those observed in wild-type SIV-infected macrophages (Figure 2C). Viral cDNA products were barely detectable in macrophages infected in the presence of tenofovir (Figure 2C). This result was further confirmed by an increase in productive infection as evidenced by levels of RT activity in culture supernatants (Figure 2D). SAMHD1 knock-down treatment significantly increased SIV vpx viral production above its scrambled and mock conditions. These results confirm that SAMHD1 depletion is necessary and sufficient to compensate for the macrophage infectivity defect created by vpx deletion, even though Vpx has functions besides SAMHD1 degradation [18, 59, 60].

HIV-1 Does Not Alter the Antiviral Environment Created by SAMHD1

Although HIV-1 appeared capable of infecting macrophages without altering SAMHD1 or dNTP levels, there remained the possibility that HIV-1 harbors an unknown function to nullify the antiviral environment. If this were the case, one would predict that macrophages infected with HIV-1 would exhibit increased permissivity to superinfection by vpx-deleted SIV. Macrophages were first infected for 2 hours with either HIV-1 or SIVwt and were then super-infected with a GFP-expressing HIV-1, SIVwt, or SIV vpx. Three to 4 days after infection, the frequency of GFP-positive macrophages was assessed by flow cytometry (Figure 3A). As expected, macrophages were completely refractory to SIV vpx infection, and prior infection with SIVwt normalized SIV vpx infection of macrophages to SIVwt levels ($P < 0.001$) (Figure 3B). The susceptibility of macrophages to SIV vpx infection was also markedly augmented ($P < 0.001$) by loading SIV vpx with Vpx *in trans* (SIV vpx +Vpx) as evidenced by GFP-positive cells (Figure 3B). In contrast, pre-infection of macrophages with HIV-1 did not augment SIV vpx infection of macrophages based on GFP levels (Figure 3B). HIV-1 pre-infection was not able to alter the intracellular environment in a way that would allow reverse transcription of SIV vpx; only the addition of Vpx *in trans* could bring SIV vpx cDNA to levels seen with wild-type SIV infection (Figure 3B). While macrophages were already infectable by HIV-1-GFP, that infectivity was increased (approximately 3 fold) when macrophages were pre-infected with SIVwt ($P < 0.01$) (Figure 3C). However, an increase was also observed when macrophages were first infected with SIVwt and super-infected with SIVwt-GFP ($P < 0.05$) (Figure 3B). Collectively, these results indicate that HIV-1-infected macrophages remain restricted to infection by vpx-deleted SIV, and that HIV-1 infects macrophages without altering the SAMHD1 antiviral environment that otherwise completely restricts vpx-deleted SIV.

Construction and Validation of RT-SHIV.

The data outlined above indicate that HIV-1 infection of macrophages occurs despite SAMHD1 restriction and suggest that this ability might be intrinsic to HIV-1 itself. It has been proposed that the differential sensitivity of HIV-1 and SIV to SAMHD1 is dictated by the K_m of their reverse transcriptases, such that the K_m of HIV-1 RT allows more efficient dNTP incorporation. [7, 17, 37, 40]. This would predict that exchange of HIV-1 and SIV reverse transcriptases should exchange the sensitivity to SAMHD1 restriction. Therefore, we constructed RT-SHIV, a chimeric virus in which the SIV RT gene was replaced by that of

HIV-1. Briefly, EMP-PCR was used to clone the p66 region of HIV-1 into a wild-type or a *vpx*-deleted SIV backbone (SIV_{smm} PBj) to create RT-SHIV_{wt} and RT-SHIV_{vpx}, respectively (Figure 4A). We first validated the functionality of the RT-SHIVs by assessing their sensitivity to nucleoside (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the indicator cell line sMAGI, which is infectable by both HIV-1 and SIV [42]. HIV-1 RT is sensitive to both nevirapine and tenofovir, whereas SIV RT is sensitive to tenofovir but insensitive to nevirapine [61]. The infectivity of the RT-SHIVs in sMAGI cells, as assessed by qPCR for viral cDNA, was comparable to that observed for the parental SIVs (Figure 4B). While SIV infection was insensitive to nevirapine, no cDNA products were observed in RT-SHIV_{wt} or RT-SHIV_{vpx}-infected cells in the presence of nevirapine (Figure 4B). Furthermore, cDNA synthesis by both SIV and RT-SHIV was inhibited by tenofovir demonstrating that cDNA products were generated *de novo*. The ability of nevirapine to inhibit RT-SHIV but not SIV infection demonstrated that the RT-SHIVs contained a functional HIV-1 RT in an SIV backbone.

Reverse Transcriptase Does Not Dictate Sensitivity to SAMHD1

We next evaluated whether the chimeric SIV harboring HIV-1 RT (RT-SHIV_{wt}) and its *vpx*-deleted counterpart (RT-SHIV_{vpx}), exhibited reduced sensitivity to SAMHD1 restriction. If indeed HIV-1 RT is capable of operating in a low dNTP environment, we would predict that Vpx would be dispensable for macrophage infection by RT-SHIV. Macrophages were infected with SIV and RT-SHIV variants, and infection was monitored by cDNA production (Figure 5A, B) and by the presence of SIV Gag-positive cells by flow cytometry (Figure 5C, D). Infectivity was compared to wild-type and *vpx*-deleted SIV (SIV_{wt} and SIV_{vpx}, respectively). The RT-SHIV harboring an intact *vpx* gene (RT-SHIV_{wt}) was infectious in macrophages as evidenced by *de novo* cDNA generation (Figure 5C) and Gag-positive cells (Figure 5D), albeit at slightly lower levels than SIV_{wt}. In contrast, both SIV_{vpx} and RT-SHIV_{vpx} were not infectious in macrophages as visualized by cDNA levels (Figure 5A, C) and by numbers of Gag-positive cells (Figure 5B, D). The infectivity of both SIV_{vpx} and RT-SHIV_{vpx} in macrophages was restored when Vpx was packaged in these viruses *in trans*, as evidenced by cDNA synthesis (Figure 5A, C) and Gag-positive cells (Figure 5B, D). The results were obtained using an HIV RT inserted in a SIV_{smm} PBj backbone, and we further confirmed these results using chimeric viruses in which HIV-1 RT was inserted into an SIV_{mac} 316e backbone. The wild-type and *vpx*-deleted chimeras were similarly functional as shown by differential sensitivity to nevirapine (Supplemental Figure A). Furthermore, in macrophages, the chimeras were only capable of undergoing reverse transcription in the presence of Vpx (Supplemental Figure B). Collectively, these results demonstrate that chimeric SIVs harboring a functional HIV-1 RT are nevertheless restricted by SAMHD1 and dependent on Vpx for infection of macrophages. This also indicates that reverse transcriptase does not solely account for the ability of HIV-1 to evade SAMHD1 restriction.

SIV Reverse Transcriptase Does Not Confer Increased Sensitivity of HIV-1 to SAMHD1

Although HIV-1 RT did not appear to confer resistance to SAMHD1 restriction, we wondered if the SIV RT might be inherently more susceptible to low dNTP levels, thus conferring increased sensitivity to SAMHD1. To assess this, we constructed the reciprocal

chimeric virus RT-HSIV (Figure 6A); again, EMP-PCR was used to clone the p66 region of SIVsmm PBj into a HIV-1 backbone (HIV-1 LAIada). RT-HSIV was infectious in sMAGI cells as evidenced by *de novo* cDNA generation (Figure 6B). Furthermore, while HIV-1 was sensitive to nevirapine, the RTHSIV chimera was insensitive to nevirapine (Figure 6B). As expected, both wild-type HIV-1 and the RT-HSIV were sensitive to tenofovir (Figure 6B). These data suggest RT-HSIV contains a functional SIV RT in a HIV-1 backbone. We next assessed whether the chimeric HIV-1 containing SIV RT would exhibit increased sensitivity to SAMHD1 restriction. If differences in efficiency of dNTP usage underscored the differential sensitivity of SIV and HIV-1 to SAMHD1 restriction, we would predict that SIV RT within an HIV-1 backbone would increase the sensitivity of this chimeric virus to SAMHD1. Following macrophage infection, Gag-positive cells were present for HIV-1 (25% +/- 3.2) and at lower levels for RT-HSIV (5.4% +/- 1.5) (Figure 6D). However, the level of cDNA products generated with wild-type HIV-1 and the chimeric RT-HSIV were comparable (Figure 6C) and tenofovir substantially reduced cDNA synthesis demonstrating that the cDNA products generated in the absence of tenofovir were bona fide products of reverse transcription (Figure 6C). This was surprising because in the absence of Vpx, SIV RT is incapable of reverse transcribing in macrophages (see, for example, Figure 3C, and 5A). Since the RT-HSIV had the capacity to reverse transcribe in macrophages in which SAMHD1 was active, this suggests that the HIV-1 genome harbors a determinant, apart from RT, enabling SIV RT to operate in the low dNTP environment created by SAMHD1. It is unfortunate that despite reverse transcription, RTHSIV does not produce as much Gag in infected macrophages as HIV-1 (Figure 6D); like many chimeric viruses, this construct may have unforeseen issues with viral fitness unrelated to SAMHD1 restriction [47, 62]. In order to observe the impact of SAMHD1 on RT-HSIV, we pre-infected macrophages with SIVwt for 2 hours and then superinfected them with RT-HSIV. As expected, the Vpx from SIVwt greatly boosts the RT-HSIV cDNA levels (Figure 6E); based on qPCR alone, it would appear that RT-HSIV is quite dependent upon SAMHD1 elimination. However, this phenotype is also observed with HIV-1 cDNA levels [22, 23, 63]. Interestingly, despite the massive increase in reverse transcripts, our data show that HIV-1 has a more modest increase in productive infection after SIVwt pre-infection (Figure 3C). We believe the elimination of SAMHD1 boosts HIV-1 (or RT-HSIV) cDNA generation to supraphysiological levels, which are not needed for HIV-1 to productively infect macrophages, as evidenced by Gag- and GFP-positivity (Figures 1C, 1G, 3C, and 6D). Therefore, although it has been previously shown that SAMHD1 affects HIV-1 infection, we argue that SAMHD1 elimination is not necessary for HIV-1 (or RT-HSIV) to reverse transcribe in macrophages; Vpx and SAMHD1 knockdown only serve to boost HIV-1 infectivity but are not necessary for it.

DISCUSSION

Myeloid cells pose several obstacles to infection by primate lentiviruses. As terminally differentiated, non-dividing cells, the nuclear envelope would be expected to limit nuclear translocation of the viral reverse transcription or pre-integration complex. Nevertheless, primate lentiviruses have evolved a mechanism, still poorly understood, that allows the reverse transcription complex to gain nuclear access and drive integration within host cell DNA [64]. Secondly, dNTPs, which are the substrates for reverse transcription and cDNA

generation, are rate limiting in myeloid cells due to SAMHD1 activity. Nevertheless, primate lentiviruses have evolved to circumvent this potent restriction which enables infection of macrophages and quiescent CD4+ T cells [1, 65]. While the mechanism for SAMHD1 evasion employed by SIV and HIV-2 centers on the Vpx protein, it is not known how HIV-1, which does not harbor a Vpx-like activity, evades SAMHD1 during macrophage infection.

Our study reveals the following main points:

- HIV-1 efficiently infects macrophages in the face of SAMHD1 restriction. Macrophages that are restricted to infection by Vpx-deleted SIV, nevertheless remain permissive to HIV-1 infection
- HIV-1 does not modulate the antiviral environment created by SAMHD1 such that HIV-1-infected macrophages remain restricted to infection by Vpx-deleted SIV.
- In contrast to what has been reported in the literature, the lower sensitivity of HIV-1 to SAMHD1-mediated restriction is not dictated by reverse transcriptase. Therefore, inserting the HIV-1 RT into SIV did not confer reduced SAMHD1 sensitivity to the chimeric SIV.
- A chimeric HIV-1 containing an SIV RT exhibited some capacity to synthesize cDNA in the face of SAMHD1 restriction suggesting that a determinant in the HIV-1 genome, that is outside the RT region, may be involved in the reduced sensitivity of HIV-1 to SAMHD1 restriction.

Together, these data suggest that even though SAMHD1 has some effect on HIV-1, the HIV-1 genome harbors a determinant(s) that underscores its ability to infect macrophages in the face of active SAMHD1. This reveals a fundamental difference between HIV-1 and its relatives HIV-2 and SIV, which are unable to infect macrophages unless SAMHD1 is eliminated and dNTP concentrations are increased to levels suitable for reverse transcription of viral cDNA.

Previous reports have indicated that the reverse transcriptases of HIV-1 and SIV differ in several different kinetic parameters including fidelity and processivity [37, 40, 66–68]. Some studies have demonstrated that HIV-1 reverse transcriptases have a lower K_m for dNTPs than those of SIV, allowing them to catalyze cDNA synthesis at low dNTP levels, thereby negating the need to eliminate SAMHD1 altogether [40]. To test this, we replaced the reverse transcriptase of SIV with that of HIV-1 (Figure 4) and tested its ability to reverse transcribe in the presence or absence of Vpx. Surprisingly, RT-SHIV, which contains HIV RT in an SIV backbone, was only able to reverse transcribe when Vpx was present (Figure 5). In other words, the RT-SHIV behaved much like wild-type SIV in that it was dependent on Vpx-mediated SAMHD1 elimination for infection of macrophages. The reciprocal experiment further bolsters this idea because RT-HSIV, which contains SIV RT in an HIV-1 backbone, was still able to reverse transcribe in macrophages without any Vpx activity (Figure 6). This suggests that intrinsic differences in SIV and HIV-1 reverse transcriptases do not explain the ability of HIV-1 to infect macrophages without Vpx. Rather, it points to a

determinant within the HIV-1 genome, apart from RT, that dictates the resistance of HIV-1 to SAMHD1 restriction.

There is the possibility that another viral accessory protein (Vif, Vpr, Vpu, or Nef) may contribute to SAMHD1 evasion by HIV-1. Vpr, which is the Vpx paralog in HIV-1, has not been proven to be necessary for HIV-1 or SIV infection of macrophages [69, 70]. However, due to its close similarity to Vpx, Vpr could have some other modulating functions of the cellular milieu that work in concert with other viral proteins to promote infection. We previously demonstrated that HIV-1 *vpr* appears incapable of substituting for *vpx* in the SIV genome [19]. One could hypothesize that there is some other restriction factor besides SAMHD1 that is targeted by both Vpx and HIV-1. For example, 1 study found that a Vpx mutant incapable of SAMHD1 degradation was still able to boost lentiviral infection in non-permissive cells [63]. However, because SAMHD1 knock-down creates permissive conditions for SIV *vpx* infection, it appears that SAMHD1 is the key factor blocking SIV *vpx* infection as well as the main target for Vpx (Figure 2). The inability of HIV-1 to create a permissive environment for SIV *vpx* infection of macrophages, is further demonstrated in the current study where we show that infection with HIV-1 did not render macrophages permissive to infection by SIV *vpx* (Figure 3). At face value, this indicates that the HIV-1 genome does not in fact, harbor a determinant that helps nullify the antiviral conditions created SAMHD1. However, those experiments rely on such a factor acting *in trans* and do not rule out the possibility that the determinant in the HIV-1 genome may act *in cis* to permit reverse transcription in the hostile dNTP environment created by SAMHD1 expression.

Our study further argues against any modifying effect of HIV-1 on SAMHD1 levels. HIV-1 did not alter levels of SAMHD1 or dNTPs in our study (Figure 1). In addition, although the phosphorylation status of SAMHD1 has been shown to affect its ability to restrict infection [13, 71, 72], our preliminary data do not show any change in phosphorylation status after infection by HIV-1 (data not shown). Not affecting SAMHD1 may even be an adaptation by HIV-1 to avoid detection by of innate immunity. With less reverse transcription occurring, HIV-1 would not trigger certain cytosolic DNA sensors like cGAS [73–76]. Despite these reports however, we observed that macrophages that are permissive to HIV-1 remain non-permissive to super-infection by SIV *vpx* which demonstrates that the antiviral environment created by SAMHD1 is not modulated by HIV-1 (Figure 3). Instead, our data indicate that HIV-1 retains the capacity to infect macrophages in the face of SAMHD1 restriction because it is incompletely suppressed by the antiviral conditions created by SAMHD1. Further studies will be needed to identify and characterize the mechanism underscoring the resistance of HIV-1 to the SAMHD1 antiviral environment.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

ACKNOWLEDGMENTS

We are grateful to Olivier Schwartz of Institute Pasteur for the Alexa-488 Anti-SAMHD1 (I-1918) antibody and to lab members Francesc Cunyat, Jennifer Rainho, and Jessica Salinas for technical assistance.

FUNDING

We acknowledge grant support from National Institutes of Health (MH100942, MH093306, MH116701) to M.S., grants (AI136581 and GM104198) to B.K., and grant (AI131568) to Hartigan-O'Connor. We acknowledge support from the Miami Center for AIDS Research (CFAR) at the University of Miami Miller School of Medicine which is funded by a grant (P30AI073961) from the National Institutes of Health (NIH).

REFERENCES

1. Simon V, Bloch N, Landau NR. Intrinsic host restrictions to HIV-1 and mechanisms of viral escape. *Nat Immunol.* 2015;16(6):546–53. PubMed PMID: . doi: 10.1038/ni.3156 [PubMed: 25988886]
2. Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, Dragin L, Bloch N, Maudet C, Bertrand M, Gramberg T, Pancino G, Priet S, Canard B, Laguette N, Benkirane M, Transy C, Landau NR, Kim B, Margottin-Goguet F. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. *Nat Immunol* 2012;13(3):223–8. PubMed PMID: Pubmed Central PMCID: 3771401. doi: 10.1038/ni.2236 [PubMed: 22327569]
3. Franzolin E, Pontarin G, Rampazzo C, Miazzi C, Ferraro P, Palumbo E, Reichard P, Bianchi V. The deoxynucleotide triphosphohydrolase SAMHD1 is a major regulator of DNA precursor pools in mammalian cells. *Proc Natl Acad Sci U S A* 2013;110(35):14272–7. PubMed PMID: Pubmed Central PMCID: 3761606. doi: 10.1073/pnas.1312033110 [PubMed: 23858451]
4. Sattentau QJ, Stevenson M. Macrophages and HIV-1: An Unhealthy Constellation. *Cell Host Microbe* 2016;19(3):304–10. PubMed PMID: Pubmed Central PMCID: PMC5453177. doi: 10.1016/j.chom.2016.02.013 [PubMed: 26962941]
5. Amie SM, Bambara RA, Kim B. GTP is the primary activator of the anti-HIV restriction factor SAMHD1. *J Biol Chem* 2013;288(35):25001–6. PubMed PMID: Pubmed Central PMCID: 3757166. doi: 10.1074/jbc.C113.493619 [PubMed: 23880768]
6. Goldstone DC, Ennis-Adeniran V, Hedden JJ, Groom HC, Rice GI, Christodoulou E, Walker PA, Kelly G, Haire LF, Yap MW, de Carvalho LP, Stoye JP, Crow YJ, Taylor IA, Webb M. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. *Nature* 2011;480(7377):379–82. PubMed PMID: . doi: 10.1038/nature10623 [PubMed: 22056990]
7. Kim B, Nguyen LA, Daddacha W, Hollenbaugh JA. Tight interplay among SAMHD1 protein level, cellular dNTP levels, and HIV-1 proviral DNA synthesis kinetics in human primary monocyte-derived macrophages. *J Biol Chem* 2012;287(26):21570–4. PubMed PMID: Pubmed Central PMCID: 3381122. doi: 10.1074/jbc.C112.374843 [PubMed: 22589553]
8. Gramberg T, Kahle T, Bloch N, Wittmann S, Mullers E, Daddacha W, Hofmann H, Kim B, Lindemann D, Landau NR. Restriction of diverse retroviruses by SAMHD1. *Retrovirology* 2013;10:26 PubMed PMID: Pubmed Central PMCID: 3605129. doi: 10.1186/1742-4690-10-26 [PubMed: 23497255]
9. Kaushik R, Zhu X, Stranska R, Wu Y, Stevenson M. A cellular restriction dictates the permissivity of nondividing monocytes/macrophages to lentivirus and gammaretrovirus infection. *Cell Host Microbe* 2009;6(1):68–80. PubMed PMID: Pubmed Central PMCID: 2777639. doi: 10.1016/j.chom.2009.05.022 [PubMed: 19616766]
10. Kim ET, White TE, Brandariz-Nunez A, Diaz-Griffero F, Weitzman MD. SAMHD1 restricts herpes simplex virus 1 in macrophages by limiting DNA replication. *J Virol.* 2013;87(23):12949–56. PubMed PMID: Pubmed Central PMCID: 3838123. doi: 10.1128/JVI.02291-13 [PubMed: 24067963]
11. Berger A, Sommer AF, Zwarg J, Hamdorf M, Welzel K, Esly N, Panitz S, Reuter A, Ramos I, Jatiani A, Mulder LC, Fernandez-Sesma A, Rutsch F, Simon V, Konig R, Flory E. SAMHD1-deficient CD14+ cells from individuals with Aicardi-Goutieres syndrome are highly susceptible to HIV-1 infection. *PLoS Pathog* 2011;7(12):e1002425 PubMed PMID: Pubmed Central PMCID: 3234228. doi: 10.1371/journal.ppat.1002425 [PubMed: 22174685]
12. Sze A, Olagnier D, Lin R, van Grevenynghe J, Hiscott J. SAMHD1 host restriction factor: a link with innate immune sensing of retrovirus infection. *J Mol Biol* 2013;425(24):4981–94. PubMed PMID: . doi: 10.1016/j.jmb.2013.10.022 [PubMed: 24161438]

13. Ryoo J, Choi J, Oh C, Kim S, Seo M, Kim SY, Seo D, Kim J, White TE, Brandariz-Nunez A, Diaz-Griffero F, Yun CH, Hollenbaugh JA, Kim B, Baek D, Ahn K. The ribonuclease activity of SAMHD1 is required for HIV-1 restriction. *Nat Med* 2014;20(8):936–41. PubMed PMID: Pubmed Central PMCID: 4318684. doi: 10.1038/nm.3626 [PubMed: 25038827]
14. Cribier A, Descours B, Valadao AL, Laguette N, Benkirane M. Phosphorylation of SAMHD1 by cyclin A2/CDK1 regulates its restriction activity toward HIV-1. *Cell Rep*. 2013;3(4):1036–43. PubMed PMID: . doi: 10.1016/j.celrep.2013.03.017 [PubMed: 23602554]
15. Pauls E, Jimenez E, Ruiz A, Permanyer M, Ballana E, Costa H, Nascimiento R, Parkhouse RM, Pena R, Riveiro-Munoz E, Martinez MA, Clotet B, Este JA, Bofill M. Restriction of HIV-1 replication in primary macrophages by IL-12 and IL-18 through the upregulation of SAMHD1. *J Immunol* 2013;190(9):4736–41. PubMed PMID: . doi: 10.4049/jimmunol.1203226 [PubMed: 23526823]
16. Amie SM, Noble E, Kim B. Intracellular nucleotide levels and the control of retroviral infections. *Virology*. 2013;436(2):247–54. PubMed PMID: Pubmed Central PMCID: 3804251. doi: 10.1016/j.virol.2012.11.010 [PubMed: 23260109]
17. Diamond TL, Roshal M, Jamburuthugoda VK, Reynolds HM, Merriam AR, Lee KY, Balakrishnan M, Bambara RA, Planelles V, Dewhurst S, Kim B. Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. *J Biol Chem* 2004;279(49):51545–53. PubMed PMID: Pubmed Central PMCID: 1351161. doi: 10.1074/jbc.M408573200 [PubMed: 15452123]
18. Fletcher TM, Brichacek B, Sharova N, Newman MA, Stivahtis G, Sharp PM, Emerman M, Hahn BH, Stevenson M Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM). *EMBO J* 1996;15(22):6155–65. PubMed PMID: Pubmed Central PMCID: 452436. [PubMed: 8947037]
19. Sharova N, Wu Y, Zhu X, Stranska R, Kaushik R, Sharkey M, Stevenson M. Primate lentiviral Vpx commandeers DDB1 to counteract a macrophage restriction. *PLoS Pathog* 2008;4(5):e1000057 PubMed PMID: 18451984. Pubmed Central PMCID: 2323106. doi: 10.1371/journal.ppat.1000057
20. Liska V, Spehner D, Mehtali M, Schmitt D, Kirn A, Aubertin A-M. Localization of viral protein X in simian immunodeficiency virus macaque strain and analysis of its packaging requirements. *Journal of General Virology* 1994;75: 2955–296. [PubMed: 7964605]
21. Selig L, Pages J-C, Tanchou V, Preveral S, Berlioz-Torrent C, Liu LX, Erdtmann L, Darlix J-L, Benardous R, Benichou S. Interaction with the p6 Domain of the Gag Precursor Mediates Incorporation into Virions of Vpr and Vpx Proteins from Primate Lentiviruses. *J Virol* 1999;73(1): 592–600. [PubMed: 9847364]
22. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, Florens L, Washburn MP, Skowronski J. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. *Nature* 2011;474(7353):658–61. PubMed PMID: Pubmed Central PMCID: 3179858. doi: 10.1038/nature10195 [PubMed: 21720370]
23. Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segal E, Yatim A, Emiliani S, Schwartz O, Benkirane M. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. *Nature* 2011;474(7353):654–7. PubMed PMID: Pubmed Central PMCID: 3595993. doi: 10.1038/nature10117 [PubMed: 21613998]
24. McCulley A, Ratner L. HIV-2 viral protein X (Vpx) ubiquitination is dispensable for ubiquitin ligase interaction and effects on macrophage infection. *Virology*. 2012;427(1):67–75. PubMed PMID: Pubmed Central PMCID: 3302174. doi: 10.1016/j.virol.2012.02.002 [PubMed: 22386056]
25. Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M, Schenkova K, Ambiel I, Wabnitz G, Gramberg T, Panitz S, Flory E, Landau NR, Sertel S, Rutsch F, Lasitschka F, Kim B, Konig R, Fackler OT, Keppler OT. SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. *Nat Med* 2012;18(11):1682–7. PubMed PMID: Pubmed Central PMCID: 3828732. doi: 10.1038/nm.2964 [PubMed: 22972397]
26. Descours B, Cribier A, Chable-Bessia C, Ayinde D, Rice G, Crow Y, Yatim A, Schwartz O, Laguette N, Benkirane M. SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells. *Retrovirology* 2012;9:87 PubMed PMID: Pubmed Central PMCID: 3494655. doi: 10.1186/1742-4690-9-87 [PubMed: 23092122]

27. Hollenbaugh JA, Gee P, Baker J, Daly MB, Amie SM, Tate J, Kasai N, Kanemura Y, Kim DH, Ward BM, Koyanagi Y, Kim B. Host factor SAMHD1 restricts DNA viruses in non-dividing myeloid cells. *PLoS Pathog* 2013;9(6):e1003481 PubMed PMID: Pubmed Central PMCID: 3694861. doi: 10.1371/journal.ppat.1003481 [PubMed: 23825958]
28. Triques K, Stevenson M. Characterization of restrictions to human immunodeficiency virus type 1 infection of monocytes. *J Virol* 2004;78(10):5523–7. PubMed PMID: Pubmed Central PMCID: 400363. [PubMed: 15113933]
29. Fregoso OI, Ahn J, Wang C, Mehrens J, Skowronski J, Emerman M. Evolutionary toggling of Vpx/Vpr specificity results in divergent recognition of the restriction factor SAMHD1. *PLoS Pathog* 2013;9(7):e1003496 PubMed PMID: Pubmed Central PMCID: 3715410. doi: 10.1371/journal.ppat.1003496 [PubMed: 23874202]
30. Planelles V, Barker E. Roles of Vpr and Vpx in modulating the virus-host cell relationship. *Mol Aspects Med* 2010;31(5):398–406. PubMed PMID: Pubmed Central PMCID: 2967654. doi: 10.1016/j.mam.2010.05.002 [PubMed: 20558198]
31. Sharp PM, Bailes E, Stevenson M, Emerman M, Hahn BH. Gene acquisition in HIV and SIV. *Nature* 1996;383(6601):586–7. [PubMed: 8857532]
32. Fujita M, Nomaguchi M, Adachi A, Otsuka M. SAMHD1-Dependent and -Independent Functions of HIV-2/SIV Vpx Protein. *Front Microbiol* 2012;3:297 PubMed PMID: Pubmed Central PMCID: 3415948. doi: 10.3389/fmicb.2012.00297 [PubMed: 22908011]
33. de Silva S, Planelles V, Wu L. Differential effects of Vpr on single-cycle and spreading HIV-1 infections in CD4+ T-cells and dendritic cells. *PLoS One* 2012;7(5):e35385 PubMed PMID: Pubmed Central PMCID: 3343049. doi: 10.1371/journal.pone.0035385 [PubMed: 22570689]
34. Schwefel D, Groom HC, Boucherit VC, Christodoulou E, Walker PA, Stoye JP, Bishop KN, Taylor IA. Structural basis of lentiviral subversion of a cellular protein degradation pathway. *Nature*. 2014;505(7482):234–8. PubMed PMID: Pubmed Central PMCID: 3886899. doi: 10.1038/nature12815 [PubMed: 24336198]
35. Hartl MJ, Mayr F, Rethwilm A, Wohrl BM. Biophysical and enzymatic properties of the simian and prototype foamy virus reverse transcriptases. *Retrovirology* 2010;7:5 PubMed PMID: Pubmed Central PMCID: 2835651. doi: 10.1186/1742-4690-7-5 [PubMed: 20113504]
36. Santos-Velazquez J, Kim B. Deoxynucleoside triphosphate incorporation mechanism of foamy virus (FV) reverse transcriptase: implications for cell tropism of FV. *J Virol* 2008;82(16):8235–8. PubMed PMID: Pubmed Central PMCID: 2519572. doi: 10.1128/JVI.00088-08 [PubMed: 18508890]
37. Skasko M, Weiss KK, Reynolds HM, Jamburuthugoda V, Lee K, Kim B. Mechanistic differences in RNA-dependent DNA polymerization and fidelity between murine leukemia virus and HIV-1 reverse transcriptases. *J Biol Chem* 2005;280(13):12190–200. PubMed PMID: Pubmed Central PMCID: 1752212. doi: 10.1074/jbc.M412859200 [PubMed: 15644314]
38. Kennedy EM, Gavegnano C, Nguyen L, Slater R, Lucas A, Fromentin E, Schinazi RF, Kim B. Ribonucleoside triphosphates as substrate of human immunodeficiency virus type 1 reverse transcriptase in human macrophages. *J Biol Chem* 2010;285(50):39380–91. PubMed PMID: Pubmed Central PMCID: 2998149. doi: 10.1074/jbc.M110.178582 [PubMed: 20924117]
39. Appelberg KS, Goodenow MM. Editorial: Passive aggressive avoidance of SAMHD1 restriction by HIV-1. *J Leukoc Biol* 2015;98(1):1–3. PubMed PMID: . doi: 10.1189/jlb.4CE0215-044R [PubMed: 26130765]
40. Lenzi GM, Domaol RA, Kim DH, Schinazi RF, Kim B. Kinetic variations between reverse transcriptases of viral protein X coding and noncoding lentiviruses. *Retrovirology* 2014;11(1):111 PubMed PMID: Pubmed Central PMCID: 4282736. doi: 10.1186/s12977-014-0111-y [PubMed: 25524560]
41. Davies JQ, Gordon S. Isolation and culture of human macrophages. *Methods Mol Biol* 2005;290:105–16. PubMed PMID: . [PubMed: 15361658]
42. Charkerian B, Haigwood NL, Overbaugh J. Characterization of a CD4-Expressing Macaque Cell Line That Can Detect Virus after a Single Replication Cycle and Can Be Infected by Diverse Simian Immunodeficiency Virus Isolates. *Virology* 1995;213:386–94. [PubMed: 7491763]

43. Westervelt P, Gendelman HE, Ratner L. Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. *Proc Natl Acad Sci U S A* 1991;88:3097–101. [PubMed: 2014229]
44. Ulrich A, Andersen KR, Schwartz TU. Exponential megaprimer PCR (EMP) cloning--seamless DNA insertion into any target plasmid without sequence constraints. *PLoS One*. 2012;7(12):e53360 PubMed PMID: Pubmed Central PMCID: 3534072. doi: 10.1371/journal.pone.0053360 [PubMed: 23300917]
45. Kestler H, Kodama T, Ringler D, Marthas M, Pedersen N, Lackner A, Regier D, Sehgal P, Daniel M, King N, Desrosiers R. Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. *Science* 1990;248(4959):1109–12. [PubMed: 2160735]
46. Mori K, Rosenzweig M, Desrosiers RC. Mechanisms for adaptation of simian immunodeficiency virus to replication in alveolar macrophages. *J Virol* 2000;74(22):10852–9. [PubMed: 11044136]
47. Soderberg K, Denekamp L, Nikiforow S, Sautter K, Desrosiers RC, Alexander L. A nucleotide substitution in the tRNA(Lys) primer binding site dramatically increases replication of recombinant simian immunodeficiency virus containing a human immunodeficiency virus type 1 reverse transcriptase. *J Virol* 2002;76(11):5803–6. PubMed PMID: Pubmed Central PMCID: 137045. [PubMed: 11992009]
48. Bartz SR, Vodicka MA. Production of high-titer human immunodeficiency virus type 1 pseudotyped with vesicular stomatitis virus glycoprotein. *Methods* 1997;12(4):337–42. PubMed PMID: . doi: 10.1006/meth.1997.0487 [PubMed: 9245614]
49. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. *Nature Biotechnology* 1997;15:871–5.
50. Stevenson M, Haggerty S, Lamonica C, Mann AM, Meier C, Wasiak A. Cloning and characterization of human immunodeficiency virus type 1 variants diminished in the ability to induce syncytium-independent cytolysis. *J Virol* 1990;64(8):3792–803. [PubMed: 1695254]
51. Belshan M, Kimata JT, Brown C, Cheng X, McCulley A, Larsen A, Thippeshappa R, Hodara V, Giavedoni L, Hirsch V, Ratner L. Vpx is critical for SIVmne infection of pigtail macaques. *Retrovirology* 2012;9:32 PubMed PMID: Pubmed Central PMCID: 3353869. doi: 10.1186/1742-4690-9-32 [PubMed: 22531456]
52. Planelles V Restricted access to myeloid cells explained. *Viruses* 2011;3(9):1624–33. PubMed PMID: Pubmed Central PMCID: 3187686. doi: 10.3390/v3091624 [PubMed: 21994799]
53. Berger G, Turpin J, Cordeil S, Tartour K, Nguyen XN, Mahieux R, Cimarelli A. Functional analysis of the relationship between Vpx and the restriction factor SAMHD1. *J Biol Chem* 2012;287(49):41210–7. PubMed PMID: Pubmed Central PMCID: PMC3510820. doi: 10.1074/jbc.M112.403816 [PubMed: 23076149]
54. St. Gelais C, de Silva S, Amie SM, Coleman CM, Hoy H, Hollenbaugh JA, Kim B, Wu L. SAMHD1 restricts HIV-1 infection in dendritic cells (DCs) by dNTP depletion, but its expression in DCs and primary CD4+ T-lymphocytes cannot be upregulated by interferons. *Retrovirology* 2012;9(105).
55. Amie SM, Daly MB, Noble E, Schinazi RF, Bambara RA, Kim B. Anti-HIV host factor SAM-HD1 regulates viral sensitivity to nucleoside reverse transcriptase inhibitors via modulation of cellular deoxyribonucleoside triphosphate (dNTP) levels. *J Biol Chem* 2013;288(28):20683–91. PubMed PMID: Pubmed Central PMCID: 3711331. doi: 10.1074/jbc.M113.472159 [PubMed: 23744077]
56. Bobadilla S, Sunseri N, Landau NR. Efficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory protein. *Gene Ther* 2013;20(5):514–20. PubMed PMID: Pubmed Central PMCID: PMC4105013. doi: 10.1038/gt.2012.61 [PubMed: 22895508]
57. Brandariz-Nuñez A, Valle-Casuso JC, White TE, Nguyen L, Bhattacharya A, Wang Z, Demeler B, Amie S, Knowlton C, Kim B, Ivanov DN, Diaz-Griffero F. Contribution of oligomerization to the anti-HIV-1 properties of SAMHD1. *Retrovirology* 2013;10(131).
58. Martinez-Picado J, Zurakowski R, Buzón MJ, Stevenson M. Episomal HIV-1 DNA and its relationship to other markers of HIV-1 persistence. *Retrovirology* 2018;15(1).
59. Belshan M, Mahnke LA, Ratner L. Conserved amino acids of the human immunodeficiency virus type 2 Vpx nuclear localization signal are critical for nuclear targeting of the viral preintegration complex in non-dividing cells. *Virology* 2006;346:118–26. [PubMed: 16325220]

60. Mueller SM, Jung R, Weiler S, Lang SM. Vpx proteins of SIVmac239 and HIV-2ROD interact with the cytoskeletal protein alpha-actinin 1. *J Gen Virol* 2004;85:3291–03. [PubMed: 15483243]
61. Shaharabany M, Hizi A. The Catalytic Functions of Chimeric Reverse Transcriptases of Human Immunodeficiency Viruses Type 1 and Type 2. *J Biol Chem* 1992;267(6):3674–8. [PubMed: 1371274]
62. Ambrose Z, Boltz V, Palmer S, Coffin JM, Hughes SH, Kewalramani VN. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. *J Virol* 2004;78(24):13553–61. PubMed PMID: Pubmed Central PMCID: 533891. doi: 10.1128/JVI.78.24.13553-13561.2004 [PubMed: 15564466]
63. Reinhard C, Bottinelli D, Kim B, Luban J. Vpx rescue of HIV-1 from the antiviral state in mature dendritic cells is independent of the intracellular deoxynucleotide concentration. *Retrovirology* 2014;11(12).
64. Bukrinsky M, Haggerty S, Dempsey M, Sharova N, Adzhubel A, Spitz L, Lewis P, Goldfarb D, Emerman M, Stevenson M. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells *Nature* 1993;365(6447):666–9. [PubMed: 8105392]
65. Zack JA, Kim SG, Vatakis DN. HIV restriction in quiescent CD4(+) T cells. *Retrovirology* 2013;10:37 PubMed PMID: Pubmed Central PMCID: PMC3626626. doi: 10.1186/1742-4690-10-37 [PubMed: 23557201]
66. Bakhanashvili M, Hizi A. Fidelity of the reverse transcriptase of human immunodeficiency virus type 2. *FEBS Lett* 1992;306(2–3):151–6. PubMed PMID: . [PubMed: 1378791]
67. Diamond TL, Kimata J, Kim B. Identification of a simian immunodeficiency virus reverse transcriptase variant with enhanced replicational fidelity in the late stage of viral infection. *J Biol Chem* 2001;276(26):23624–31. PubMed PMID: . doi: 10.1074/jbc.M102496200 [PubMed: 11325971]
68. Manns A, Konig H, Baier M, Kurth R, Grosse F. Fidelity of reverse transcriptase of the simian immunodeficiency virus from African green monkey. *Nucleic Acids Res* 1991;19(3):533–7. PubMed PMID: Pubmed Central PMCID: 333644. [PubMed: 1707165]
69. Gibbs J, Regier D, Desrosiers R. Construction and in vitro properties of HIV-1 mutants with deletions in “nonessential” genes. *AIDS Res Hum Retroviruses* 1994;4:343–50.
70. Gibbs J, Regier D, Desrosiers R. Construction and in vitro properties of SIVmac mutants with deletions in “nonessential” genes. *AIDS Res Hum Retroviruses* 1994;5:607–16.
71. Cribier A, Descours B, Valadão AL, Laguette N, Benkirane M. Phosphorylation of SAMHD1 by cyclin A2/CDK1 regulates its restriction activity toward HIV-1. *Cell Rep* 2013;3(4):1036–43. [PubMed: 23602554]
72. White TE, Brandariz-Nunez A, Valle-Casuso JC, Amie S, Nguyen LA, Kim B, Tuzova M, Diaz-Griffero F. The retroviral restriction ability of SAMHD1, but not its deoxynucleotide triphosphohydrolase activity, is regulated by phosphorylation. *Cell Host Microbe* 2013;13(4):441–51. PubMed PMID: Pubmed Central PMCID: 3864637. doi: 10.1016/j.chom.2013.03.005 [PubMed: 23601106]
73. Gao D, Wu J, Wu YT, Du F, Aroh C, Yan N, Sun L, Chen ZJ. Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses. *Science* 2013;341(6148):903–6. PubMed PMID: Pubmed Central PMCID: 3860819. doi: 10.1126/science.1240933 [PubMed: 23929945]
74. Jakobsen MR, Bak RO, Andersen A, Berg RK, Jensen SB, Tengchuan J, Laustsen A, Hansen K, Ostergaard L, Fitzgerald KA, Xiao TS, Mikkelsen JG, Mogensen TH, Paludan SR. IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication. *Proc Natl Acad Sci U S A* 2013;110(48):E4571–80. PubMed PMID: Pubmed Central PMCID: 3845190. doi: 10.1073/pnas.1311669110 [PubMed: 24154727]
75. Yan N, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieberman J. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. *Nat Immunol.* 2010;11(11):1005–13. PubMed PMID: Pubmed Central PMCID: 2958248. doi: 10.1038/ni.1941 [PubMed: 20871604]
76. Lahaye X, Satoh T, Gentili M, Cerboni S, Conrad C, Hurbain I, El Marjou A, Lacabaratz C, Lelievre JD, Manel N. The capsids of HIV-1 and HIV-2 determine immune detection of the viral

cDNA by the innate sensor cGAS in dendritic cells. *Immunity* 2013;39(6):1132–42. PubMed
PMID: . doi: 10.1016/j.immuni.2013.11.002 [PubMed: 24269171]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 1. SIV but not HIV-1 eliminates SAMHD1 and augments cellular dNTP levels in macrophages.

(A-B) FACS analysis of viral Gag and SAMHD1 levels in uninfected macrophages and in macrophages infected with HIV-1 or SIV. Individual FACS profiles together with combined profiles are indicated in panel A and B respectively. (C-D) Quantitative (geometric means) and statistical comparisons of viral Gag (C) and SAMHD1 (D). (E) Western blot analysis (cropped image) of SAMHD1 levels in uninfected, HIV-1, SIVwt, and SIV Δ vpx-infected macrophages together with quantitative and statistical analysis of SAMHD1 levels (F) are indicated. Lysates for Western blotting and intracellular dNTP analysis (H) were generated 1

day post-infection. Cells from the same infection were sampled 4 days post-infection for intracellular Gag staining. (G) The percentage of viral Gag-positive cells from the same experiments as samples collected for Western blotting and dNTP measurements and above the Western blot for that particular experiment. Results represent pooled data from 3 or more replicate experiments \pm SD. Welch's t-test: * $P < 0.05$ ** $P < 0.01$ *** $P < 0.001$ **** $P < 0.0001$.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 2. SAMHD1 knock-down renders macrophages permissive to infection by *vpx*-deleted SIV.

(A) Complete elimination of SAMHD1 expression in macrophages through successive (3X) rounds of siRNA transfection. Levels of SAMHD1 in macrophages 14 days after transfection with SAMHD1-specific or scrambled siRNAs or mock-transfected macrophages are shown by Western blot (cropped image). (B) SAMHD1 levels were quantitated by densitometry for statistical comparisons of SAMHD1 as normalized to GAPDH levels. (C-D) SAMHD1 knock-down permits macrophage infection by SIV *vpx*. Fourteen days after siRNA transfection, macrophages were infected with wild-type (wt) or *vpx*-deleted (SIV *vpx*) variants, and infection of siRNA transfected macrophages was gauged from the levels of full-length viral cDNA by qPCR analysis (C) and by viral reverse transcriptase activity in culture supernatants (D) at the indicated intervals post-infection. Bar graphs represent pooled data from 3 or more replicate experiments \pm SD. Welch's t-test: * $P < 0.05$ ** $P < 0.01$ *** $P < 0.001$ **** $P < 0.0001$.




Figure 3. HIV-1 preinfection does not render macrophages permissive to superinfection by *vpx*-deleted SIV.

(A) Experimental design. Macrophages were first infected with HIV-1 or SIV and after 2 hours, superinfected with wild-type (SIVwt) or *vpx*-deleted (SIV *vpx*) SIV variants expressing GFP. (B) Macrophage infection by wild-type and *vpx*-deleted SIV variants was gauged from the number of GFP positive cells at 3–4 days post-infection. To gauge possible contribution of macrophage autofluorescence to the GFP signal and to ascertain *de novo* infection, tenofovir, which inhibits HIV-1 and SIV reverse transcriptases, was added to duplicate cultures 2 hours prior to infection. (C) SIVwt pre-infection also increased macrophage permissivity to HIV-1-GFP infection. Bar graphs represent pooled data from 3

or more replicate experiments \pm SD. Welch's t-test: * $P < 0.05$ ** $P < 0.01$ *** $P < 0.001$
**** $P < 0.0001$.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 4. Construction and validation of RT-SHIV in which HIV-1 RT is inserted into an SIV backbone.

(A) schematic of RT-SHIV in which the HIV-1 reverse transcriptase was inserted into an SIV backbone. (B) differential sensitivity of RT-SHIV to the RT inhibitors nevirapine (NVP) and tenofovir (TFV) was assessed in sMAGI cells (susceptible to infection by HIV-1 and SIV). Tenofovir is active against HIV-1 and SIV RT while nevirapine is only active against HIV-1. sMAGI cells were pretreated with the RT inhibitors for 2 hours and then infected with wild type or *vpx*-deleted SIV variants or with RT-SHIV variants harboring a functional (RT-SHIV_{wt}) or inactive *vpx* (RT-SHIV_{Δvpx}) open reading frame. Infection of sMAGI cells was gauged from levels of viral cDNA by qPCR at the indicated intervals post-infection. Results represent pooled data from 3 or more replicate experiments \pm SD. * $P < 0.05$ ** $P < 0.01$ *** $P < 0.001$ **** $P < 0.0001$.




Figure 5. HIV-1 RT, within the context of an SIV backbone, requires Vpx for reverse transcription in macrophages.

(A-B) Permissivity of macrophages to SIV infection is absolutely dependent on Vpx.

Macrophages were infected with wild type or *vpx*-deleted SIV variants and infection was gauged by levels of viral cDNA by qPCR (A) or Gag-positive cells by FACS (B).

Introduction of Vpx *in trans* (SIV *vpx* + Vpx) permitted macrophage infection by *vpx*-

deleted SIV. (C-D) Permissivity of macrophages to RT-SHIV infection is absolutely

dependent on Vpx. Macrophages were infected with RT-SHIV variants containing intact

(RT-SHIVwt) or defective (RT-SHIV *vpx*) *vpx* open reading frames and infection gauged

by qPCR for viral cDNA (C) and FACS for Gag-positive cells (D). As with parental

SIV *vpx*, introduction of Vpx *in trans* rescued *vpx*-defective RT-SHIV (RT-SHIV *vpx*

+Vpx). Bar graphs represent pooled data from 3 or more replicate experiments +/- SD.

Statistical comparisons for panels A and C are based on Area Under the Curve analysis, and

on Welch's t-test for panels B and D) *P < 0.05 **P < 0.01 ***P < 0.001 ****P < 0.0001.




Figure 6. SIV RT, within the context of an HIV-1 backbone, does not require Vpx for reverse transcription in macrophages.

(A) Schematic of RT-HSIV depicting HIV-1 harboring an SIV RT. (B) RTHSIV infection of sMAGI cells is sensitive to inhibition by tenofovir but not nevirapine. sMAGI cells were infected with wild type HIV-1 (HIV-1) or HIV-1 harboring SIV RT (RT-HSIV) and viral cDNA synthesis assessed by qPCR at the indicated intervals post-infection. (C) Macrophages are equally permissive to infection by wild type HIV-1 and HIV-1 containing SIV RT (RT-HSIV) despite the absence of Vpx. Macrophage infection was assessed by qPCR for viral cDNA at the indicated intervals post-infection. (D) Levels of Gag-positive

cells were assessed by flow cytometry after HIV-1 or RT-HSIV infection. (E) Macrophages were infected for 2 hours with SIVwt, then superinfected with RT-HSIV. RT-HSIV cDNA levels were measured by qPCR. Bar graphs represent pooled data from 3 or more replicate experiments \pm SD. Statistical comparisons for panels B, C, and E are based on Area Under the Curve analysis. Panel D statistical comparisons were based on Welch's t-test. * $P < 0.05$ ** $P < 0.01$ *** $P < 0.001$ **** $P < 0.0001$.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript